Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age
- 3 May 2019
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 143 (3) , 515-523
Abstract
Contrast enhancement (CE) is found in 10–60% of low-grade gliomas. Its prognostic significance is controversial, and its correlation with IDH mutations and 1p/19q codeletion is elusive. The aim of this study is to investigate whether CE is associated with molecular characteristics of low-grade gliomas and uncover its prognostic value.Keywords
This publication has 43 references indexed in Scilit:
- Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 casesJournal of Neurosurgery, 2013
- Low-grade (WHO II) and anaplastic (WHO III) gliomas: differences in morphology and MRI signal intensitiesEuropean Radiology, 2013
- IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survivalNeuro-Oncology, 2013
- Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802Journal of Clinical Oncology, 2012
- Conventional MRI evaluation of gliomasBritish Journal of Radiology, 2011
- Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspectiveActa Neuropathologica, 2010
- Prognostic significance of imaging contrast enhancement for WHO grade II gliomasNeuro-Oncology, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- Survival rates and patterns of care for patients diagnosed with supratentorial low‐grade gliomasCancer, 2006
- Imaging Correlates of Molecular Signatures in OligodendrogliomasClinical Cancer Research, 2004